Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
Published on 06/09/2025 at 07:14 pm BST
Reuters
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 282.55 DKK | -0.19% |
|
-0.46% | -13.13% |
| 06-11 | Health Care Up, but Not by Much, on Rotation Back to Tech - Health Care Roundup | DJ |
| 06-11 | Novo Nordisk Reports Cybersecurity Incident Involving IT System Access | MT |
Mr. Lars Fruergaard Jørgensen is a Vice President at European Federation of Pharmaceutical Industries & Assns, a Vice Chairman-Supervisory Board at Carlsberg A/S, a Member-Supervisory Board at Carlsberg Breweries A/S, a President & Chief Executive Officer at Novo Nordisk Ltd., a President & Chief Executive Officer at Novo Nordisk A/S and a Chairman at Harno Invest A/S. He is on the Board of Directors at Carlsberg A/S and Carlsberg Breweries A/S. Mr. Jørgensen was previously employed as a Member-Supervisory Board by Innate Pharma SA, a Vice President-Finance & Information Technology by Novo Nordisk Pharmaceutical SAS, and a Chairman by NNE Pharmaplan A/S. He also served on the board at ZymoGenetics, Inc. and NNIT A/S. He received his graduate degree from the University of Aarhus.
Employees
67,900
Sector
Pharmaceuticals
Calendar
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
282.55DKK
Average target price
311.78DKK
Spread / Average Target
+10.34%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVO B Stock
- News Novo Nordisk A/S
- Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
Select your edition
All financial news and data tailored to specific country editions
